Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FT-4202, a selective pyruvate kinase R activator for sickle cell disease.
Ericsson A, Richard DJ, Wilker E, Lancia DR Jr, Fessler S, Troccolo P, Zheng X, Toms A, Dinsmore C, Yao L, Kuypers FA, Larkin S, Marcotte D, Fulzele K, Ribadeneira M, Guichard SM, Marshall G. Ericsson A, et al. Among authors: ribadeneira m. Exp Hematol. 2024 Nov 15;141:104673. doi: 10.1016/j.exphem.2024.104673. Online ahead of print. Exp Hematol. 2024. PMID: 39549740 Free article.
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.
Saraf SL, Hagar R, Idowu M, Osunkwo I, Cruz K, Kuypers FA, Brown RC, Geib J, Ribadeneira M, Schroeder P, Wu E, Forsyth S, Kelly PF, Kalfa TA, Telen MJ. Saraf SL, et al. Among authors: ribadeneira m. Blood Adv. 2024 Aug 27;8(16):4459-4475. doi: 10.1182/bloodadvances.2023012467. Blood Adv. 2024. PMID: 38640200 Free PMC article. Clinical Trial.
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.
Forsyth S, Schroeder P, Geib J, Vrishabhendra L, Konstantinidis DG, LaSalvia K, Ribadeneira MD, Wu E, Kelly P, Kalfa TA. Forsyth S, et al. Among authors: ribadeneira md. Clin Pharmacol Drug Dev. 2022 May;11(5):654-665. doi: 10.1002/cpdd.1058. Epub 2022 Jan 12. Clin Pharmacol Drug Dev. 2022. PMID: 35019238 Free PMC article. Clinical Trial.
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly T, Morrow L, Hompesch M, Hellerstein MK, Li K, Johansson L, Kelly PF. Beysen C, et al. Among authors: ribadeneira m. Diabetes Obes Metab. 2021 Mar;23(3):700-710. doi: 10.1111/dom.14272. Epub 2020 Dec 21. Diabetes Obes Metab. 2021. PMID: 33289350 Free PMC article. Clinical Trial.
KCNQ channel openers reverse depressive symptoms via an active resilience mechanism.
Friedman AK, Juarez B, Ku SM, Zhang H, Calizo RC, Walsh JJ, Chaudhury D, Zhang S, Hawkins A, Dietz DM, Murrough JW, Ribadeneira M, Wong EH, Neve RL, Han MH. Friedman AK, et al. Among authors: ribadeneira m. Nat Commun. 2016 May 24;7:11671. doi: 10.1038/ncomms11671. Nat Commun. 2016. PMID: 27216573 Free PMC article.
EEG-β/γ spectral power elevation in rat: a translatable biomarker elicited by GABA(Aα2/3)-positive allosteric modulators at nonsedating anxiolytic doses.
Christian EP, Snyder DH, Song W, Gurley DA, Smolka J, Maier DL, Ding M, Gharahdaghi F, Liu XF, Chopra M, Ribadeneira M, Chapdelaine MJ, Dudley A, Arriza JL, Maciag C, Quirk MC, Doherty JJ. Christian EP, et al. Among authors: ribadeneira m. J Neurophysiol. 2015 Jan 1;113(1):116-31. doi: 10.1152/jn.00539.2013. Epub 2014 Sep 24. J Neurophysiol. 2015. PMID: 25253471 Free article.
Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors: in vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.
Sturino CF, Bousquet Y, James CA, DeRoy P, Duplessis M, Edwards PJ, Halmos T, Minville J, Morency L, Morin S, Thavonekham B, Tremblay M, Duan J, Ribadeneira M, Garneau M, Pelletier A, Tremblay S, Lamorte L, Bethell R, Cordingley MG, Rajotte D, Simoneau B. Sturino CF, et al. Among authors: ribadeneira m. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3967-75. doi: 10.1016/j.bmcl.2013.04.043. Epub 2013 Apr 25. Bioorg Med Chem Lett. 2013. PMID: 23673016
24 results